Delays in access to affordable medicines: putting policy into perspective

Open Access Article

<< Previous

Next >>

Contents Vol 36(4)

doi:10.1071/AH11110

Journal of the Australian Healthcare & Hospitals Association

	Search




	Advanced Search



	Journal Home

	About the Journal

	Editorial Committee

	Contacts

	For Advertisers



	Content

	Online Early

	Current Issue

	Just Accepted

	All Issues

	Sample Issue



	For Authors

	General Information

	Instructions to Authors

	Submit Article

	Open Access



	For Referees

	Referee Guidelines

	Review Article

	Call for Reviewers




	For Subscribers

	Subscription Prices

	Customer Service

	Print Publication Dates

e-Alerts

Subscribe to our Email Alert or

feeds for the latest journal papers.

Connect with AHR

Connect with CP

Delays in access to affordable medicines: putting policy into perspective

Alison Pearce ^A ^B, Kees van Gool ^A, Philip Haywood ^A and Marion Haas ^A

^A Centre for Health Economics Research and Evaluation, University of Technology, PO Box 123, Broadway, NSW 2007, Australia. Emails: kees.vangool@chere.uts.edu.au, phil.haywood@chere.uts.edu.au, marion.haas@chere.uts.edu.au
^B Corresponding author. Email: alison.pearce@chere.uts.edu.au

Australian Health Review 36(4) 412-418 http://dx.doi.org/10.1071/AH11110
Submitted: 8 November 2011 Accepted: 19 April 2012 Published: 15 October 2012





	Full Text



	PDF (206 KB)



	Export Citation

Print

Abstract

Background. To save costs, the Australian Government recently deferred approval of seven new medicines recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) for up to 7 months.

Objectives. The aim of this research is to examine the timelines of PBAC applications following approval by the Therapeutic Goods Administration (TGA), allowing the recent Cabinet delays to be considered in the context of the overall medicines approval process.

Methods. All new chemical entities and products for new indications approved in 2004 by the Australian Drug Evaluation Committee (ADEC) were identified. Outcomes of PBAC meetings from 2004 to 2010 were then searched to identify if and when these products were reviewed by PBAC.

Results. ADEC recommended 63 eligible products for registration in 2004. Of the 113 submissions made to PBAC for these products, 66 were successful. Only 43% of the products were submitted to PBAC within 2 years, with an average 17-month delay from TGA approval of a product to consideration by the PBAC.

Conclusions. Cabinet decisions to defer listing of new medicines delays access to new treatments. This occurred in addition to other longer delays, earlier in the approval process for medicines, resulting in a significant impact on the overall timeliness of listing.

What is known about the topic? There is evidence that the time from registration of new drugs on the TGA to their listing for subsidised availability is increasing. The government’s recent decision to delay the listing of seven new drugs for subsidisation raised concerns about the potential for additional delays to impact the accessibility of new, affordable medicines for patients.

What does this paper add? This paper examines delays at various stages in the process of approval for pharmaceutical subsidies on the Pharmaceutical Benefits Scheme (PBS), putting the deferral of new medicine listings in the overall context of the approval process. It identifies the potential role of pharmaceutical companies and product sponsors in delaying access to new, affordable medicines early in the approval process.

What are the implications for practitioners? Delays in the subsidisation of medicines, wherever they occur in the process, not only reduce patient access, but may also lead to pressure in other areas of the health care system to finance such medicines. This makes these results of particular interest to clinician managers, health care managers and policy makers.

References

[1] The Senate Finance and Public Administration Committee. The Government’s administration of the Pharmaceutical Benefits Scheme. Canberra: Senate Printing Unit; 2011. Available from: http://www.aph.gov.au/senate/committee/fapa_ctte/pharma_benefits_scheme/index.htm [verified September 2011]

[2] Australian Government Department of Health and Ageing. The listing steps. Commonwealth of Australia; Available from: http://www.pbs.gov.au/info/industry/listing/listing-steps [verified August 2011]

[3] Mental Health Council of Australia. Submission to the Senate Finance and Public Administration Reference Committee Inquiry into the Governments Administration of the PBS. 2011. Available from: <http://www.mhca.org.au/documents/submissions/MHCA%20Submission%20to%20the%20Senate%20Inquiry%20into%20the%20Government’s%20adminsitration%20of%20the%20PBS.pdf> [verified August 2011]

[4] Bennett CA. Opening remarks to Senate Finance and Public Administration Reference Committee Inquiry into the Governments Administration of the PBS 2011. Available from: <https://www.chf.org.au/pdfs/chf/Opening-remarks-PBS-Senate-Inquiry-July-2011.pdf> [verified September 2011]

[5] Australian Drug Evaluation Committee. Gazettal Notice Therapeutic Goods Act 1989 Australian Drug Evaluation Committee Recommendations. Commonwealth of Australia Gazette GN 8, 25 February 2004. Available from: http://www.tga.gov.au/archive/committees-adec-resolutions-0232.htm [verified September 2011]

[6] Australian Drug Evaluation Committee. Gazettal Notice Therapeutic Goods Act 1989 Australian Drug Evaluation Committee Recommendations. Commonwealth of Australia Gazette GN 17, 28 April 2004. Available from: http://www.tga.gov.au/archive/committees-adec-resolutions-0233.htm [verified September 2011]

[7] Australian Drug Evaluation Committee. Gazettal Notice Therapeutic Goods Act 1989 Australian Drug Evaluation Committee Recommendations. Commonwealth of Australia Gazette GN 27, 7 July 2004. vailable from: http://www.tga.gov.au/archive/committees-adec-resolutions-0234.htm [verified September 2011]

[8] Australian Drug Evaluation Committee. Gazettal Notice Therapeutic Goods Act 1989 Australian Drug Evaluation Committee Recommendations. Commonwealth of Australia Gazette GN 35, 1 September 2004. Available from: http://www.tga.gov.au/archive/committees-adec-resolutions-0235.htm [verified September 2011]

[9] Australian Drug Evaluation Committee. Gazettal Notice Therapeutic Goods Act 1989 Australian Drug Evaluation Committee Recommendations. Commonwealth of Australia Gazette GN 45, 10 November 2004. Available from: http://www.tga.gov.au/archive/committees-adec-resolutions-0236.htm [verified September 2011]

[10] Australian Drug Evaluation Committee. Gazettal Notice Therapeutic Goods Act 1989 Australian Drug Evaluation Committee Recommendations. Commonwealth of Australia Gazette GN 2, 19 January 2005. Available from: http://www.tga.gov.au/archive/committees-adec-resolutions-0237.htm [verified September 2011]

[11] Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Australian Government Department of Health and Ageing; 2008. Available from: http://www.health.gov.au/internet/main/publishing.nsf/content/AECB791C29482920CA25724400188EDB/$File/PBAC4.3.2.pdf [verified September 2011]

[12] Pharmaceutical Benefits Advisory Committee. Recommendations made by PBAC. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-outcomes-by-meeting [verified September 2011]

[13] Pretium. Drug Tracker Report: July 2010. 2010. Available from: http://www.pretium.com.au/drugtrackerPDF/Drug%20Tracker%20-%2010%2007.pdf [verified August 2011]

[14] Australian Government Department of Health and Ageing. Memorandum of understanding with Medicines Australia. September 2010. Available from: http://www.pbs.gov.au/info/industry/useful-resources/memorandum[verified February 2012]

[15] Medicines Australia. Submission to the Senate Finance and Public Administration Committee Inquiry into: ‘The Government’s Administration of the Pharmaceutical Benefits Scheme’. 18th July 2011. Available from: http://medicinesaustralia.com.au/files/2010/02/20110715-sub-deferrals-senate-inquiry-FINAL-lodged.pdf [verified February 2012]

[16] Australian Government Department of Health and Ageing. Framework for the introduction of parallel TGA and PBAC processes. Canberra: Australian Government Department of Health and Ageing; 2011. Available from: http://www.pbs.gov.au/info/publication/factsheets/shared/framework-for-introduction-of-parallel-TGA-and-PBAC-processes [verified October 2011]

[17] Australian Government CommLaw. National Health (Pharmaceuticals and Vaccines - Cost Recovery) Regulations 2009. 2009. Available from: http://www.comlaw.gov.au/Details/F2009L04013 [verified August 2011]

[18] Wilson P. Funding the PBS machine. Medical Observer 2009. Available from: http://www.medicalobserver.com.au/news/funding-the-pbs-machine [verified February 2012]

[19] CommercialEyes. The cost of PBS cost recovery 2010. Available from: http://commercialeyes.com.au/whats-news/the-cost-of-pbs-cost-recovery [verified February 2012]

[20] Pharmaceutical Benefits Advisory Committee. Independent review of the impact of PBS cost recovery 2011. Available from: http://www. pbs.gov.au/info/news/2011/09/independent-review-impact-of-pbs-cost-recovery [verified February 2012]

[21] Lingaratnam SM, Kirsa SW, Mellor JD, Jackson J, Crellin W, Fitzsimons M, et al A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008. Aust Health Rev 2011; 35: 204–10.

[22] Australian Health Insurance Association. New South Wales and Queensland Exceptional Drugs List. Canberra: Australian Health Insurance Association; 2011. Available from: http://www.ahia.org.au/wp-content/uploads/EDL-Update-1-May-2011.pdf [verified October 2011]

[23] Australian Government Department of Foreign Affairs and Trade. Australia–United States Free Trade Agreement 2004. Available from: http://www.dfat.gov.au/fta/ausfta/final-text/index.html [verified February 2012]

Legal & Privacy | Contact Us | Help